286 related articles for article (PubMed ID: 21860028)
1. Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation.
Tacken PJ; Ginter W; Berod L; Cruz LJ; Joosten B; Sparwasser T; Figdor CG; Cambi A
Blood; 2011 Oct; 118(15):4111-9. PubMed ID: 21860028
[TBL] [Abstract][Full Text] [Related]
2. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
[TBL] [Abstract][Full Text] [Related]
3. Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation.
van Kooyk Y; Unger WW; Fehres CM; Kalay H; García-Vallejo JJ
Mol Immunol; 2013 Sep; 55(2):143-5. PubMed ID: 23158834
[TBL] [Abstract][Full Text] [Related]
4. Toll-Like Receptor 4 Triggering Promotes Cytosolic Routing of DC-SIGN-Targeted Antigens for Presentation on MHC Class I.
Horrevorts SK; Duinkerken S; Bloem K; Secades P; Kalay H; Musters RJ; van Vliet SJ; García-Vallejo JJ; van Kooyk Y
Front Immunol; 2018; 9():1231. PubMed ID: 29963041
[TBL] [Abstract][Full Text] [Related]
5. In vivo targeting of human DC-SIGN drastically enhances CD8⁺ T-cell-mediated protective immunity.
Hesse C; Ginter W; Förg T; Mayer CT; Baru AM; Arnold-Schrauf C; Unger WW; Kalay H; van Kooyk Y; Berod L; Sparwasser T
Eur J Immunol; 2013 Oct; 43(10):2543-53. PubMed ID: 23784881
[TBL] [Abstract][Full Text] [Related]
6. Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens.
Fehres CM; Kalay H; Bruijns SC; Musaafir SA; Ambrosini M; van Bloois L; van Vliet SJ; Storm G; Garcia-Vallejo JJ; van Kooyk Y
J Control Release; 2015 Apr; 203():67-76. PubMed ID: 25656175
[TBL] [Abstract][Full Text] [Related]
7. Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells.
Unger WW; van Beelen AJ; Bruijns SC; Joshi M; Fehres CM; van Bloois L; Verstege MI; Ambrosini M; Kalay H; Nazmi K; Bolscher JG; Hooijberg E; de Gruijl TD; Storm G; van Kooyk Y
J Control Release; 2012 May; 160(1):88-95. PubMed ID: 22366522
[TBL] [Abstract][Full Text] [Related]
8. Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation.
Cohn L; Chatterjee B; Esselborn F; Smed-Sörensen A; Nakamura N; Chalouni C; Lee BC; Vandlen R; Keler T; Lauer P; Brockstedt D; Mellman I; Delamarre L
J Exp Med; 2013 May; 210(5):1049-63. PubMed ID: 23569326
[TBL] [Abstract][Full Text] [Related]
9. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody.
Tacken PJ; de Vries IJ; Gijzen K; Joosten B; Wu D; Rother RP; Faas SJ; Punt CJ; Torensma R; Adema GJ; Figdor CG
Blood; 2005 Aug; 106(4):1278-85. PubMed ID: 15878980
[TBL] [Abstract][Full Text] [Related]
10. Mouse DC-SIGN/CD209a as Target for Antigen Delivery and Adaptive Immunity.
Schetters STT; Kruijssen LJW; Crommentuijn MHW; Kalay H; Ochando J; den Haan JMM; Garcia-Vallejo JJ; van Kooyk Y
Front Immunol; 2018; 9():990. PubMed ID: 29867967
[TBL] [Abstract][Full Text] [Related]
11. Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells.
Chatterjee B; Smed-Sörensen A; Cohn L; Chalouni C; Vandlen R; Lee BC; Widger J; Keler T; Delamarre L; Mellman I
Blood; 2012 Sep; 120(10):2011-20. PubMed ID: 22791285
[TBL] [Abstract][Full Text] [Related]
12. No advantage of cell-penetrating peptides over receptor-specific antibodies in targeting antigen to human dendritic cells for cross-presentation.
Tacken PJ; Joosten B; Reddy A; Wu D; Eek A; Laverman P; Kretz-Rommel A; Adema GJ; Torensma R; Figdor CG
J Immunol; 2008 Jun; 180(11):7687-96. PubMed ID: 18490772
[TBL] [Abstract][Full Text] [Related]
13. Multivalent glycopeptide dendrimers for the targeted delivery of antigens to dendritic cells.
García-Vallejo JJ; Ambrosini M; Overbeek A; van Riel WE; Bloem K; Unger WW; Chiodo F; Bolscher JG; Nazmi K; Kalay H; van Kooyk Y
Mol Immunol; 2013 Apr; 53(4):387-97. PubMed ID: 23103377
[TBL] [Abstract][Full Text] [Related]
14. In situ Delivery of Antigen to DC-SIGN(+)CD14(+) Dermal Dendritic Cells Results in Enhanced CD8(+) T-Cell Responses.
Fehres CM; van Beelen AJ; Bruijns SCM; Ambrosini M; Kalay H; Bloois LV; Unger WWJ; Garcia-Vallejo JJ; Storm G; de Gruijl TD; Kooyk YV
J Invest Dermatol; 2015 Sep; 135(9):2228-2236. PubMed ID: 25885805
[TBL] [Abstract][Full Text] [Related]
15. Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN.
Cruz LJ; Tacken PJ; Pots JM; Torensma R; Buschow SI; Figdor CG
Biomaterials; 2012 Jun; 33(16):4229-39. PubMed ID: 22410170
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments.
Kang TH; Lee JH; Bae HC; Noh KH; Kim JH; Song CK; Shin BC; Hung CF; Wu TC; Park JS; Kim TW
Immunol Lett; 2006 Aug; 106(2):126-34. PubMed ID: 16844231
[TBL] [Abstract][Full Text] [Related]
17. DC-SIGN promotes exogenous MHC-I-restricted HIV-1 antigen presentation.
Moris A; Nobile C; Buseyne F; Porrot F; Abastado JP; Schwartz O
Blood; 2004 Apr; 103(7):2648-54. PubMed ID: 14576049
[TBL] [Abstract][Full Text] [Related]
18. A mouse C kappa-specific T cell clone indicates that DC-SIGN is an efficient target for antibody-mediated delivery of T cell epitopes for MHC class II presentation.
Schjetne KW; Thompson KM; Aarvak T; Fleckenstein B; Sollid LM; Bogen B
Int Immunol; 2002 Dec; 14(12):1423-30. PubMed ID: 12456590
[TBL] [Abstract][Full Text] [Related]
19. Carbohydrate-mediated targeting of antigen to dendritic cells leads to enhanced presentation of antigen to T cells.
Adams EW; Ratner DM; Seeberger PH; Hacohen N
Chembiochem; 2008 Jan; 9(2):294-303. PubMed ID: 18186095
[TBL] [Abstract][Full Text] [Related]
20. DC-SIGN, but not sDC-SIGN, can modulate IL-2 production from PMA- and anti-CD3-stimulated primary human CD4 T cells.
Martinez O; Brackenridge S; El-Idrissi Mel-A; Prabhakar BS
Int Immunol; 2005 Jun; 17(6):769-78. PubMed ID: 15944195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
